Award Number: W81XWH-06-1-0630 TITLE: A Targeted Mulifunctional Platform for Imaging and Treatment of Breast Cancer and Its Metastases Based on Adenoviral Vectors and Magnetic Nanoparticles

Viruses have a documented history for being used in treatment and prevention of diseases for centuries, with their application in vaccination strategies as a prime early example. In more recent history, viral vectors have been employed for gene and cell therapy of tumors. In this regard, the increased understanding of the aberrant molecular pathways underlying the process of tumorigenesis has rationalized genetic correction of these pathophysiological processes using viral vector based gene and cell therapy approaches. For example, viruses have been genetically engineered to develop oncolytic potency or mediate long-term gene expression. Also, viral vectors carrying therapeutic genes or targeting molecules have been loaded into cells, which can be exploited as delivery vehicles for these therapeutic payloads to the desired target site. However, issues pertaining to viral and cell targeting as well as host immune response elicited upon viral or cell administration remain to be addressed. In summary, the plasticity of the viral structure has rendered them amenable for the development of unique gene and cell therapy approaches, for the treatment of tumors. _____________________________________________________________________________________________________________

[1]  R. Desmond,et al.  A three-dimensional assay for measurement of viral-induced oncolysis , 2007, Cancer Gene Therapy.

[2]  S. Russell,et al.  Engineering oncolytic measles virus to circumvent the intracellular innate immune response. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Shuming Nie,et al.  Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. , 2007, Journal of the American Chemical Society.

[4]  A. Rivera,et al.  Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer , 2007, International journal of cancer.

[5]  Shuming Nie,et al.  Quantum dots for in vivo molecular and cellular imaging. , 2007, Methods in molecular biology.

[6]  E. Genden,et al.  Interleukin‐12 Expression Enhances Vesicular Stomatitis Virus Oncolytic Therapy in Murine Squamous Cell Carcinoma , 2007, The Laryngoscope.

[7]  S. Indraccolo,et al.  Angiogenesis meets immunology: cytokine gene therapy of cancer. , 2007, Molecular aspects of medicine.

[8]  S. Indraccolo,et al.  Anti-angiogenic gene therapy of cancer: current status and future prospects. , 2007, Molecular aspects of medicine.

[9]  J. Mathis,et al.  Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma , 2007, Breast Cancer Research and Treatment.

[10]  A. Oberg,et al.  The Use of a Tropism-Modified Measles Virus in Folate Receptor–Targeted Virotherapy of Ovarian Cancer , 2006, Clinical Cancer Research.

[11]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[12]  V. Zharov,et al.  Combination of viral biology and nanotechnology: new applications in nanomedicine. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[13]  P. Nielsen,et al.  Enhanced delivery of cell-penetrating peptide–peptide nucleic acid conjugates by endosomal disruption , 2006, Nature Protocols.

[14]  M. Barry,et al.  Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. , 2006, Virology.

[15]  O. Danos,et al.  Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice , 2006, Gene Therapy.

[16]  T. Park,et al.  Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. , 2006, Bioconjugate chemistry.

[17]  D. Grimm,et al.  Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. , 2006, Cardiovascular research.

[18]  C. Contag,et al.  Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy , 2006, Science.

[19]  Vladimir P Zharov,et al.  Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. , 2006, Nano letters.

[20]  Sam C. Noureddini,et al.  Generation and selection of targeted adenoviruses embodying optimized vector properties. , 2006, Virus research.

[21]  D. Curiel,et al.  Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses , 2006, Molecular Cancer Therapeutics.

[22]  D. Dhar,et al.  Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. , 2006, Cancer research.

[23]  D. Curiel,et al.  Transductional targeting of adenovirus vectors for gene therapy , 2006, Cancer Gene Therapy.

[24]  Vladimir P Zharov,et al.  Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[25]  R. Franceschi,et al.  Biological Approaches to Bone Regeneration by Gene Therapy , 2005, Journal of dental research.

[26]  M. Chillón,et al.  Gutless adenovirus: last-generation adenovirus for gene therapy , 2005, Gene Therapy.

[27]  L. Old,et al.  CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.

[28]  D. Curiel,et al.  Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors , 2005, Gene Therapy.

[29]  A. Gaggar,et al.  Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.

[30]  S. Woo,et al.  Treatment of multi‐focal colorectal carcinoma metastatic to the liver of immune‐competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus , 2005, International journal of cancer.

[31]  R. Alemany,et al.  Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors , 2005, Cancer Gene Therapy.

[32]  A. Beaudet,et al.  PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile , 2005, Gene Therapy.

[33]  D. Curiel,et al.  Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation , 2005, Journal of Virology.

[34]  C. Kuo,et al.  Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy , 2005, Cancer Gene Therapy.

[35]  J. Mehta,et al.  Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells , 2005, Cancer Gene Therapy.

[36]  C. James,et al.  Rescue and propagation of fully retargeted oncolytic measles viruses , 2005, Nature Biotechnology.

[37]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[38]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[39]  M. Andreeff,et al.  Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.

[40]  N. Bessis,et al.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.

[41]  K. Norman,et al.  Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Rivera,et al.  Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. , 2004, Virology.

[43]  D. P. O'Neal,et al.  Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. , 2004, Cancer letters.

[44]  S. Ni,et al.  Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors , 2004, Journal of Virology.

[45]  M. Aprahamian,et al.  Carrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases , 2004, International journal of cancer.

[46]  D. Curiel,et al.  A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma , 2004, Gene Therapy.

[47]  T. Khurana,et al.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions , 2004, Journal of Molecular Medicine.

[48]  Florian Kreppel,et al.  Long-Term Transgene Expression in Proliferating Cells Mediated by Episomally Maintained High-Capacity Adenovirus Vectors , 2004, Journal of Virology.

[49]  J. Shah,et al.  Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12 , 2004, Clinical Cancer Research.

[50]  C. Rancourt,et al.  Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer. , 2003, Cytotherapy.

[51]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Curiel,et al.  Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. , 2003, Gastroenterology.

[53]  D. Curiel,et al.  Approaches to Utilize Mesenchymal Progenitor Cells as Cellular Vehicles , 2003, Stem cells.

[54]  S. Kitano,et al.  Oncolytic viral therapy for human pancreatic cancer cells by reovirus. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  D. Kayda,et al.  Optimization of the generation and propagation of gutless adenoviral vectors. , 2003, Human gene therapy.

[56]  D. Curiel,et al.  Construction and Characterization of Adenovirus Serotype 5 Packaged by Serotype 3 Hexon , 2002, Journal of Virology.

[57]  R. Vile,et al.  The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider , 2002, Cancer Gene Therapy.

[58]  M. Andreeff,et al.  Advances in gene transfer into haematopoietic stem cells by adenoviral vectors , 2002, Expert opinion on biological therapy.

[59]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[60]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[61]  F. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  D. Curiel,et al.  Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. , 2002, Human gene therapy.

[63]  K. Norman,et al.  Reovirus oncolysis of human breast cancer. , 2002, Human gene therapy.

[64]  C. Ring Cytolytic viruses as potential anti-cancer agents. , 2002, The Journal of general virology.

[65]  D. Curiel,et al.  Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. , 2002, Cancer research.

[66]  J. He,et al.  Retroviral vectors for gene therapy of AIDS and cancer. , 2001, Current opinion in molecular therapeutics.

[67]  D. Curiel,et al.  Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo , 2001, Nature Biotechnology.

[68]  S. Nishikawa,et al.  Reovirus as an oncolytic agent against experimental human malignant gliomas. , 2001, Journal of the National Cancer Institute.

[69]  A. Flake,et al.  Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. , 2001, Blood cells, molecules & diseases.

[70]  B. Thomson Viruses and apoptosis , 2001, International journal of experimental pathology.

[71]  H. Yoshiji,et al.  Intravenous readministration of an adenoviral vector performed long after the initial administration failed to induce re-expression of the original transgene in rats. , 2001, International journal of oncology.

[72]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[73]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[74]  M. Calderwood,et al.  Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells , 2000, British Journal of Cancer.

[75]  E. Wimmer,et al.  Intergeneric poliovirus recombinants for the treatment of malignant glioma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Grill,et al.  Targeting of adenoviral vectors through a bispecific single-chain antibody , 2000, Cancer Gene Therapy.

[77]  D. Kirn,et al.  In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. , 2000, Cancer research.

[78]  James M. Allen,et al.  Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes , 2000, Journal of Virology.

[79]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[80]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[81]  I. Takanami,et al.  Tumor-Associated Macrophage Infiltration in Pulmonary Adenocarcinoma: Association with Angiogenesis and Poor Prognosis , 1999, Oncology.

[82]  W. Wold,et al.  Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. , 1999, Current opinion in immunology.

[83]  G. Coukos,et al.  Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  R. Price,et al.  Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement , 1999, Gene Therapy.

[85]  C. Miller,et al.  Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.

[86]  C. Halbert,et al.  Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.

[87]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[88]  N. Dyson The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[89]  C. Caskey,et al.  An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  S. Ponnazhagan,et al.  Recombinant Human Parvovirus B19 Vectors: Erythroid Cell-Specific Delivery and Expression of Transduced Genes , 1998, Journal of Virology.

[91]  A. Beaudet,et al.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity , 1998, Nature Genetics.

[92]  D. Curiel,et al.  Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  J. Flint,et al.  Viral transactivating proteins. , 1997, Annual review of genetics.

[94]  R. Hawkins,et al.  The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery , 1997, Gene Therapy.

[95]  A. Gown,et al.  Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[96]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[97]  M. Rudnicki,et al.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[98]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[99]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[100]  D. Curiel,et al.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism , 1996, Journal of virology.

[101]  J. Wilson,et al.  Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. , 1996, Human gene therapy.

[102]  P. Wen,et al.  In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. , 1996, Human gene therapy.

[103]  B. Trapnell,et al.  Gene therapy using adenoviral vectors. , 1994, Current opinion in biotechnology.

[104]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[105]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[106]  C. Lewis,et al.  Tumour‐associated leucocytes: Friends or foes in breast carcinoma , 1994, The Journal of pathology.

[107]  S. Ben-Efraim,et al.  Therapeutical effect of activated human macrophages on a human tumor line growing in nude mice , 1994, Medical oncology.

[108]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[109]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[110]  G. Akusjärvi,et al.  Proteins with transcription regulatory properties encoded by human adenoviruses. , 1993, Trends in microbiology.

[111]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[112]  P. Hearing,et al.  Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection , 1989, Journal of virology.

[113]  E. Bridge,et al.  Redundant control of adenovirus late gene expression by early region 4 , 1989, Journal of virology.

[114]  F. Moolten Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.

[115]  Craig W. Reynolds,et al.  Distribution of peritoneal macrophage populations after intravenous injection in mice: differential effects of eliciting and activating agents. , 1983, Journal of the Reticuloendothelial Society.

[116]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.

[117]  W. Cassel,et al.  Newcastle disease virus as an antineoplastic agent , 1965, Cancer.

[118]  S. Russell,et al.  Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  Jinwoo Cheon,et al.  Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.

[120]  D. Curiel,et al.  Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application , 2007, Cancer Gene Therapy.

[121]  A. Barberis,et al.  An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery , 2006, Gene Therapy.

[122]  G. Bertino,et al.  Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C , 2006, Clinical drug investigation.

[123]  P. Monaci,et al.  Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector , 2005, International journal of cancer.

[124]  G. Hashiro,et al.  The preferential cytotoxicity of reovirus for certain transformed cell lines , 2005, Archives of Virology.

[125]  M. Barry,et al.  Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[127]  E. Poeschla,et al.  Lentiviral vectors. , 2005, Advances in biochemical engineering/biotechnology.

[128]  R. Kontermann,et al.  Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single‐chain diabody (scDb) adapter that binds to fiber knob and HMWMAA , 2004, International journal of cancer.

[129]  D. Nettelbeck,et al.  Tumor-busting viruses. , 2003, Scientific American.

[130]  M. Dewhirst,et al.  Early wound healing exhibits cytokine surge without evidence of hypoxia. , 2000, Annals of surgery.

[131]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[132]  D. Gridley,et al.  Antitumor effect of vaccinia virus in glioma model. , 1999, Oncology research.

[133]  C. Rüegg,et al.  Clinical applications of TNF-alpha in cancer. , 1998, Current opinion in immunology.

[134]  J. Chamberlain,et al.  Production and Characterization of Improved Adenovirus Vectors with the E 1 , E 2 b , and E 3 Genes Deleted , 1998 .

[135]  W. Wold,et al.  E3 transcription unit of adenovirus. , 1995, Current topics in microbiology and immunology.

[136]  G. Elion The chemotherapeutic exploitation of virus-specified enzymes. , 1980, Advances in enzyme regulation.